The Financial Environment For Cannabis Brands

By Michael Harlow, CPA, Partner, CohnReznick

In a Nov. 25 advisory, the FDA issued safety concerns about products containing CBD, and sent warning letters to 15 companies about making claims in violation of the Federal Food, Drug, and Cosmetic (FD&C) Act.

In short, the FDA has only approved CBD for its tested and patented medical use in the drug Epidiolex, and otherwise considers the compound to be an unapproved food additive prohibited for use in human or animal food or as a dietary supplement.

Months earlier, Michael Harlow of CohnReznick anticipated those very concerns while speaking at a NYC conference; this video of his address is a must-see for anyone considering whether to market hemp- or marijuana-derived CBD products.

###

For more information, contact CohnReznick.com.

This content has been prepared for informational purposes, is general guidance only and does not constitute legal or professional advice. You should not act upon the information contained in this publication without first obtaining professional advice specific to, among other things, your individual facts, circumstances, and jurisdiction. No representation or warranty (express or implied) is made as to the accuracy or completeness of the information contained in this publication, and CohnReznick LLP, its partners, employees, and agents accept no liability, and disclaim all responsibility, for the consequences of you or anyone else acting, or refraining to act, in reliance on the information contained in this publication or for any decision based on it.

The post The Financial Environment for Cannabis Brands appeared first on New Frontier Data.

The preceding article is from one of our external contributors. It does not represent the opinion of Benzinga and has not been edited.

Image Sourced from Pixabay